Skip to main
CLPT

CLPT Stock Forecast & Price Target

CLPT Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ClearPoint Neuro Inc. is poised for significant growth due to its impressive topline performance, achieving 17% revenue growth in 2023 while simultaneously reducing cash burn. The company expects to sustain this momentum into 2024, with projections of over 20% revenue growth driven by an expanding partnership base and enhanced service offerings. Additionally, the successful introduction of new product approvals, record system installations, and favorable clinical publications highlight the increasing market demand for its innovative solutions, further strengthening the positive outlook for the stock.

Bears say

ClearPoint Neuro Inc demonstrated a significant reduction in cash burn throughout 2023, decreasing from $5.8 million in the first quarter to $1.2 million in the fourth quarter. While this reduction indicates improved cash management, it raises concerns regarding the company's overall financial health and long-term sustainability, particularly if revenue growth does not keep pace with operational expenses. Additionally, the expectation to continue this cash burn reduction in 2024 may not sufficiently address potential challenges related to maintaining adequate funding for ongoing development and commercialization of its products.

CLPT has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clearpoint Neuro Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clearpoint Neuro Inc (CLPT) Forecast

Analysts have given CLPT a Strong Buy based on their latest research and market trends.

According to 3 analysts, CLPT has a Strong Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clearpoint Neuro Inc (CLPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.